scispace - formally typeset
A

Amber Woolfenden

Researcher at Novartis

Publications -  10
Citations -  2491

Amber Woolfenden is an academic researcher from Novartis. The author has contributed to research in topics: Neovascularization & Angiogenesis. The author has an hindex of 8, co-authored 10 publications receiving 2346 citations. Previous affiliations of Amber Woolfenden include Massachusetts Institute of Technology.

Papers
More filters
Journal ArticleDOI

Identification of Bronchioalveolar Stem Cells in Normal Lung and Lung Cancer

TL;DR: Although bronchiolar cells and alveolar cells are proposed to be the precursor cells of adenocarcinoma, this work points to bronchioalveolar stem cells as the putative cells of origin for this subtype of lung cancer.
Journal ArticleDOI

Cellular kinetics and modeling of bronchioalveolar stem cell response during lung regeneration

TL;DR: The model demonstrated that BASC proliferation and differentiation contributes between 0 and 25% of compensatory alveolar epithelial (type I and II cell) regrowth, demonstrating that regeneration requires a substantial contribution from AECII.
Journal ArticleDOI

Reliability of the mouse model of choroidal neovascularization induced by laser photocoagulation.

TL;DR: The recommended methods for conducting experiments with the mouse laser-induced CNV model are presented to enhance reproducibility and minimize investigator bias.
Journal ArticleDOI

Discovery of Oral VEGFR-2 Inhibitors with Prolonged Ocular Retention That Are Efficacious in Models of Wet Age-Related Macular Degeneration.

TL;DR: This work employed a high-throughput in vivo screening strategy with rodent models of choroidal neovascularization and iterative compound design to identify VEGFR-2 inhibitors with potential to benefit wet AMD patients, and these compounds demonstrate preferential ocular tissue distribution and efficacy after oral administration while minimizing systemic exposure.